Drugs / 83-0060
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06402136 | Apr → Aug 2024 | — | Traws Pharma, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-30 | Traws Pharma, Inc. | Results Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor trawspharma.com ↗
Topline data indicate that administration of ratutrelvir, our product candidate for COVID, as monotherapy, for 10 days to healthy volunteers, showed no treatment related adverse events and demonstrated consistent plasma drug levels in the predicted therapeutic window. |
| 2024-05-23 | Traws Pharma, Inc. | Results Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate trawspharma.com ↗
Our initial data indicate that ratutrelvir has superior activity compared to nirmatrelvir against a range of omicron variants, based on a comparison of EC 50 . |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-30 | Traws Pharma, Inc. | Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor trawspharma.com ↗ |
| 2024-05-23 | Traws Pharma, Inc. | Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate trawspharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 83-0060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06402136 ↗ |
| Action | Inhibit | “MPro inhibitor” NCT06402136 ↗ |
| Route | Oral | “Orally administered 83-0060” NCT06402136 ↗ |